Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin therapy for depression in Bipolar II Disorder
NCT05065294Phase 2Active, not recruiting
- Sponsor
- University of California, San Francisco
- Start
- Jan 2022
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in Bipolar II disorder (BP-II), sponsored by University of California, San Francisco. Started Jan 2022; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
Bipolar II disorder (BP-II)
Beyond the preview
Go deeper on NCT05065294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065294.